# Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma.

> **NCT03202199** · NA · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 125 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DEVICE:** PET/MRI

## Key facts

- **NCT ID:** NCT03202199
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-19
- **Primary completion:** 2020-01-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03202199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03202199, "Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03202199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*